Osteoarthritis (OA) is a common systemic disorder characterized in humankind by painful, stiff, swollen joints that show cartilage loss and bony overgrowth of radiographic examination. X-rays show joint space narrowing, bony eburnation, osteophytes and bony spurs. The joint with OA is usually bony hard with irregular knobby contours and somewhat limited in motion. Cartilage loss and osteophyte formation are usually detected simultaneously but either may precede the other. The presence of these characteristic radiographic changes in the joints without clinical symptons is considered physiologic degeneration and does not warrant the diagnosis of OA which is a disorder characterized by both signs and symptoms.
PATHOLOGIC CHANGES
Earliest changes in OA start in the articular cartilage, showing a focal loss of metachromasia with swelling of cartilage matrix. Collagen fibrils are altered, developing surface irregularities and fibrillation, with progressive denudation to underlying bony cortex. New bone formation takes place in two separate locations in relation to the joint surface, at the margins of the articular process and immediately adjacent. Inflammatory reactions are common, especially in primary generalized ~Al.
CLASSIFICATION
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A form of OA involving the terminal interphalangeal joints is termed Heberden's nodes which may occur in families involving mother to daughter transmission. A less common form of primary OA is the hip disorder, malum coxae senilis. Secondary OA encompasses all forms associated with other disorders including gout, rheumatoid arthritis, ochronosis, and heritable articular diseases.
BIOCHEMICAL CHANGES
Although popular concepts regard OA as the end result of use and abuse and trauma acting on joints with individual genetic, metabolic, and developmental characteristics, this is only part of the pathogenesis in specific subsets of OA. When OA emerges, declaring itself by joint pain and characteristic anatomic radiographic patterns, alternations occur in serum proteins compatible with changes found in patients with generalized inflammatory dis orders2. These perturbations in acute phase proteins are protective and follow two patterns. The first type is increased synthesis, by the liver, of acute phase reactants. Each acute phase reactant (ceruloplasmin, acid glycoprotein, and antitrypsin) reduces inflammation3-5. The second pattern is decreased synthesis, by the liver, of carrier proteins (transferrin and albumin) which are pro-inflammatory (Table 1) 6. In addition to these inflammation-related actions by which the liver responds by altering serum proteins, there is the response of neuronal tissue and other cells making up joint structures in altering neuropeptide levels. Perturbations in peptide levels occur in the serum of the patients with OA. As with acute phase proteins, one group of peptides is anti-inflammatory while the other group is pro-inflammatory. Beta-endorphin, a 31-amino acid compound, is reduced in OA and in other rheumatic disorders 7, while substance P, an ll-amino acid compound, is pro-inflammatory and is increased (Table 2) . Beta-endorphin exerts its anti-inflammatory action by modifica-
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